Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.
J Hypertens
; 37(6): 1294-1300, 2019 06.
Article
en En
| MEDLINE
| ID: mdl-30540657
ABSTRACT
OBJECTIVE:
Concomitant treatment with angiotensin-converting enzyme (ACE) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors is increasingly common. Pharmacological studies have suggested a potential adverse drug interaction between ACE inhibitors and DPP-4 inhibitors resulting in unfavorable hemodynamic changes; very few studies have examined such an interaction between angiotensin II receptor blockers (ARBs) and DPP-4 inhibitors. We investigated blood pressure (BP) and heart rate (HR) during treatment with the DPP-4 inhibitor linagliptin in individuals receiving either ACE inhibitors or ARBs in the MARLINA-T2D trial.METHODS:
In this study, 360 individuals with type 2 diabetes and albuminuria receiving unchanged doses of ACE inhibitors or ARBs were randomized to linagliptin or placebo. Twenty-four-hour ambulatory BP monitoring, an exploratory endpoint, was conducted at baseline and after 24 weeks.RESULTS:
Ambulatory BP monitoring data were available for 208 individuals (linagliptin nâ=â111; placebo nâ=â97). Baseline meanâ±âSD 24-h SBP and DBP were 132.5â±â12.4âmmHg and 75.9â±â9.4âmmHg, respectively; mean 24-h HR was 76.3â±â10.1âbpm. At week 24, no overall effect of the DPP-4 inhibitor versus placebo was seen on mean 24-h SBP, DBP, or HR. Furthermore, in the subgroups receiving either an ACE inhibitor or an ARB, no effect on these hemodynamic parameters was seen as a result of concomitant DPP-4 inhibitor treatment.CONCLUSION:
Adding linagliptin to treatment with ACE inhibitors or ARBs was not associated with any hemodynamic changes, supporting their concomitant use in individuals with type 2 diabetes and albuminuria.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Inhibidores de la Enzima Convertidora de Angiotensina
/
Diabetes Mellitus Tipo 2
/
Inhibidores de la Dipeptidil-Peptidasa IV
/
Antagonistas de Receptores de Angiotensina
/
Linagliptina
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
J Hypertens
Año:
2019
Tipo del documento:
Article